UPDATED: Hedge fund aims to oust Depomed board for ‘troubling record’

Eric Palmer If Depomed thought it was free to chart its own course after foiling a takeover by Horizon Pharma last year, it can think again. A hedge fund practiced in the art of board ...

UPDATED: A patient in Akashi’s suspended Duchenne MD trial dies

John Carroll A little more than a week after Cambridge, MA-based Akashi Therapeutics suspended its study of a new drug for Duchenne muscular dystrophy after a patient was sent to the ...

UPDATED: Big investor to activists: J&J should break up, so please put on the heat

Tracy Staton Should Johnson & Johnson join the Big Pharma split-up club? One of its major shareholders thinks so, and it's pressing activist investors to join the cause. FiercePharma ...

UPDATED: Hedge fund’s attack on troubled Zafgen draws blood

John Carroll These days, while success and victory still have 1,000 fathers, failure and defeat have its outspoken champions as well. FierceBiotech News

UPDATED: OncoMed hits the brakes on PhII pancreatic cancer trial, shares plummet

John Carroll OncoMed slammed the brakes on a Phase II study of the cancer stem cell drug tarextumab, citing worsening response rates in the drug arm for pancreatic cancer, with red ...

UPDATED: Alkermes slammed as top depression drug fails two PhIIIs

John Carroll Alkermes reported this morning that its closely watched depression drug ALKS-5461 failed to hit the primary endpoints in the first two of three Phase III studies, slamming ...

UPDATED: Sarepta shares crash on a harsh FDA review of Duchenne’s drug

John Carroll Sarepta's quest to gain an accelerated approval for eteplirsen was subjected to some harsh scrutiny by regulators at the FDA. And the insiders concluded that much of ...

UPDATED: Shire finally gets it done, bagging Baxalta in $32B buyout

John Carroll It took a few months, but Shire has wrapped a $ 32 billion deal to acquire Baxalta, providing CEO Flemming Ornskov with the big merger that he has been promising investors. FierceBiotech ...

UPDATED: Perrigo recalls store brands of popular Zyrtec, Mucinex meds it makes for CVS, Kroger and others

Eric Palmer Perrigo is having to strip from retailers' shelves hundreds of thousands of packages of its copy of number-one allergy pill Zyrtec that are sold through CVS, Kmart, ...

UPDATED: Congressional reps urge the NIH to ‘march in’ on rising drug prices

Emily Wasserman Up in arms about rising drug prices, a cadre of lawmakers have called for Congressional action. But the lawmaking process won't happen quickly enough for some of ...

UPDATED: Sanofi’s and Regeneron’s Praluent wins top billing on UnitedHealth Group’s formulary

Eric Palmer Sanofi and Regeneron's Praluent will be UnitedHealth Group's "preferred" drug for treating superhigh LDL cholesterol. The partners said that UnitedHealth ...

UPDATED: AstraZeneca looks to bag Imbruvica rival in $5B-plus Acerta buyout: Report

John Carroll Four days after Acerta Pharma quietly posted some promising early-stage data on its Bruton's tyrosine kinase (Btk) inhibitor acalabrutinib, AstraZeneca has popped up ...
Page 1 of 612345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS